Transdel Pharmaceuticals, Inc. (OTC BB:TDLP.OB - News) is a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically delivered medications. The Company's lead topical drug, Ketotransdel(TM), utilizes the Company's innovative patented proprietary Transdel(TM) cream formulation technology to facilitate the passage of ketoprofen, an NSAID, through the skin barrier to reach targeted underlying tissue where the drug exerts its prolonged localized anti-inflammatory and analgesic effect. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management and other therapeutic areas. For more information, please visit www.transdelpharma.com.

Contact Information

4225 Executive Square
Suite 460
La Jolla, CA 92037

tel: 858-457-5300


Investor Relations



Exchange: OTCBB
Industry: Unknown
Market Cap: $21.2M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.